SignaCor: Funding, Investors & Team (Sep 2026)
SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
SignaCor has raised $330k across 1 funding round on record, the most recent a Seed of $330k announced in Mar 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SignaCor Company Profile and Key Stats
Latest funding round on record: Mar 2026.
SignaCor Funding Rounds
SignaCor Founders and Leadership Team
Contact details for the SignaCor team: 1 has a LinkedIn profile.
Start 14-day free trial →SignaCor Funding Compared to Other Biotechnology Startups
SignaCor's latest round of $330k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like SignaCor
Companies Similar to SignaCor
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
iPremom is a healthcare technology company that develops molecular diagnostic solutions for the early…
Wren Bioscience is developed to give rapid, reliable bacterial identification anywhere milk safety is…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
SignaCor Funding FAQs
What does SignaCor do?
SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
How much funding has SignaCor raised?
SignaCor has raised $330k across 1 round on record. The most recent is a Seed of $330k announced in Mar 2026.
When did SignaCor last raise funding?
SignaCor's most recent funding round on record is a Seed of $330k, announced in Mar 2026.
Who founded SignaCor?
FundedIQ lists Darach Neeson (Founder) at SignaCor.
How many employees does SignaCor have?
SignaCor is in the 1-10 employee band.
How does SignaCor's funding compare to other Biotechnology startups?
SignaCor's latest round of $330k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's SignaCor Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SignaCor is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.